Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease
- 24 March 2022
- journal article
- review article
- Published by Elsevier BV in Current Research in Translational Medicine
- Vol. 70 (3), 103343
- https://doi.org/10.1016/j.retram.2022.103343
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- SelectiveROCK2 inhibition in focal cerebral ischemiaAnnals of Clinical and Translational Neurology, 2013
- Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular HypertensionAmerican Journal of Ophthalmology, 2011
- Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular diseaseTrends in Pharmacological Sciences, 2011
- ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestorationFrontiers in Molecular Neuroscience, 2011
- The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigmaThe Korean Journal of Hematology, 2011
- Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseasesDrug Discovery Today, 2010
- Rho Kinase (ROCK) InhibitorsJournal of Cardiovascular Pharmacology, 2007
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2005
- Chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2003
- Gastrointestinal involvement in chronic graft-versus-host disease: A clinicopathologic studyTransplantation and Cellular Therapy, 2003